Table 1.

Results from randomized Phase III trials of induction chemotherapy plus rituximab in the first-line treatment of follicular lymphoma

Study	n	Regimen	RR (%)	CR (%)	TTF/PFS/EFS	OS
Hiddemann et al41	428	CHOP R-CHOP	90 96a	17 20	3-y TTF 50% 3-y TTF 75%a	3-y 86% 3-y 95%a
Herold et al42	201	MCP + I R-MCP + I	75 92a	25 50a	4-y PFS 40% 4-y PFS 71%a	4-y 74% 4-y 87%a
Marcus et al43	321	CVP R-CVP	57 81a	10 41a	TTF 7 m TTF 27 ma	4-y 77% 4-y 83%a
Salles et al44	358	CHVP + I R-CHVP + I	85 94a	34 63a	5-y EFS 37% 5-y EFS 53%a	5-y 79% 5-y 84%a
Federico et al45	534	R-CVP R-CHOP R-FM	88 93 91	67 73 72	3-y TTF 46% 3-y TTF 62%a 3-y TTF 59%a	3-y 95% for the whole series
Rummel et al46	549	R-CHOP B-R	91 93	30 40a	PFS 31.2 m PFS 69.5 ma	4-y 82% 4-y 84%

Note:

^aIndicates statistically significant differences.

Abbreviations: B-R, bendamustine and rituximab; CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisone; CHVP, cyclophosphamide, doxorubicin, etoposide, and prednisone; CR, complete response; CVP, cyclophosphamide, vincristine, and prednisone; EFS, event-free survival; I, interferon; m, months; FM, fludarabine and mitoxantrone; MCP, mitoxantrone, chlorambucil, and prednisone; n, number of patients; OS, overall survival; PFS, progression-free survival; R, rituximab; RR, response rate; TTF, time to treatment failure; y, years.